CAMBRIDGE, Mass., March 9 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. today announced that the company will present at SG Cowen Securities' 25th Annual Healthcare Conference being held in Boston, Massachusetts, March 14-17, 2005. Michael J. Astrue, President and Chief Executive Officer will present an overview and update of TKT's business activities and product pipeline at 11:20 a.m. - 12:00 p.m. Eastern Time on Wednesday, March 16, 2005. A live audio webcast of this presentation will be available at http://www.tktx.com/ on TKT's Investor Information website under the Events category. A replay will be available for approximately 30 days after the webcast.
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. In addition to its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and South America. Additional information about TKT is available on the company's website at http://www.tktx.com/.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
Daniella M. Lutz
Corporate Communications Manager
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, firstname.lastname@example.orgTranskaryotic Therapies, Inc.
CONTACT: Daniella M. Lutz, Corporate Communications Manager ofTranskaryotic Therapies, Inc., +1-617-349-0205